Prostate cancer is staged from I to IV, with higher numbers indicating more advanced disease. The stage depends on three main factors: how far the tumor has grown, whether cancer has reached nearby lymph nodes, and whether it has spread to distant parts of the body. Two additional lab values, your PSA level and a biopsy-based aggressiveness score called the Grade Group, also play a direct role in determining your stage.
How Prostate Cancer Is Staged
Doctors use a system called TNM staging. The T describes the size and extent of the primary tumor. The N indicates whether cancer cells have reached nearby lymph nodes. The M tells whether the cancer has metastasized to bones, distant lymph nodes, or other organs. Your PSA blood level and your Grade Group (a 1-to-5 scale based on how abnormal the cancer cells look under a microscope) are then combined with your TNM classification to assign an overall stage.
You may hear the terms “clinical stage” and “pathological stage.” Clinical staging is based on your physical exam, imaging, biopsy, and blood work before any treatment. Pathological staging happens after surgery, when a pathologist examines the removed prostate tissue directly. Pathological staging is generally more precise because the pathologist can see exactly how far the cancer extends.
Understanding Grade Groups
The Grade Group replaced the older Gleason score system to make grading simpler and more intuitive. It runs from 1 (least aggressive) to 5 (most aggressive), and it directly affects which stage you’re assigned. Grade Group 1 cancers are made up of well-formed, relatively normal-looking glands. Grade Group 5 cancers have largely lost any normal gland structure, which signals fast growth.
The practical difference is significant. Data from Johns Hopkins, based on over 20,000 surgical cases, shows the five-year recurrence-free rates for Grade Groups 1 through 5 were 96%, 88%, 63%, 48%, and 26%, respectively. In other words, a Grade Group 1 cancer behaves very differently from a Grade Group 4 or 5, even if the tumor size is similar.
Stage I: Cancer That Can’t Be Felt
In Stage I, the tumor is too small to be felt during a rectal exam or seen on imaging. It’s typically discovered because of a slightly elevated PSA level that led to a biopsy. To qualify as Stage I, the PSA must be below 10, the Grade Group must be 1 (the least aggressive pattern), and there’s no spread to lymph nodes or distant sites.
Treatment options at this stage range from active surveillance, where your doctor monitors the cancer with regular PSA tests and biopsies, to surgery or radiation. Many men with Stage I prostate cancer choose active surveillance because the cancer grows slowly enough that immediate treatment may not improve outcomes, and it avoids the side effects of surgery or radiation. If monitoring shows the cancer is progressing, treatment can begin then.
Stage II: Still Confined to the Prostate
Stage II means the cancer is still within the prostate but is slightly more advanced than Stage I. This can happen several ways: the tumor may now be large enough to feel on a rectal exam, the PSA may have risen to the 10-to-20 range, or the Grade Group may be higher (up to Grade Group 4). All combinations still require no lymph node involvement and no distant spread.
Stage II is broken into substages (IIA, IIB, IIC) based on these variables. A man with a small, low-grade tumor but a PSA between 10 and 20 lands in a different substage than a man with a higher-grade tumor and a lower PSA, but both are Stage II. Treatment options mirror Stage I, including active surveillance, surgery to remove the prostate, external radiation, or internal radiation using implanted radioactive seeds. The choice often depends on your age, overall health, and how aggressive the cancer cells appear.
Stage III: Cancer Growing Beyond the Prostate
Stage III is considered locally advanced. It covers several scenarios that are meaningfully different from each other, which is why it has three substages.
Stage IIIA means the cancer is still physically contained within or near the prostate, but the PSA has climbed to 20 or above. Stage IIIB means the tumor has broken through the outer wall of the prostate. It may have grown into the seminal vesicles (small glands that sit just behind the prostate) or into surrounding structures like the bladder wall or pelvic floor muscles. Stage IIIC is assigned when the biopsy shows Grade Group 5 cells, the most aggressive pattern, regardless of tumor size or PSA.
At this stage, treatment typically involves radiation combined with hormone therapy, which lowers testosterone to slow the cancer’s growth. Surgery is still an option for some men. Hormone therapy after radiation is common and may continue for months or years depending on the risk profile. For men who have urinary symptoms from the tumor pressing on surrounding structures, procedures to relieve those symptoms may also be part of the plan.
Stage IV: Cancer That Has Spread
Stage IV means the cancer has moved beyond the prostate and its immediate surroundings. Stage IVA indicates spread to nearby lymph nodes in the pelvis. Stage IVB means cancer has reached distant sites. The most common destination is bone, but it can also appear in distant lymph nodes or other organs.
Treatment at this stage focuses on controlling the disease and managing symptoms rather than curing the cancer outright. Hormone therapy is the foundation, often combined with chemotherapy. Bone-targeted treatments help prevent fractures and bone pain when the cancer has settled in the skeleton. Radiation may still be used to treat specific painful spots or to address the primary tumor. Even at Stage IV, some men respond well to treatment for years.
Survival Rates by Stage
The outlook for prostate cancer depends enormously on how far it has spread at diagnosis. According to SEER data covering 2016 through 2022, the five-year relative survival rate for localized prostate cancer (Stages I and II, where the cancer is confined to the prostate) is 100%. The rate for regional disease (Stage III or cancer in nearby lymph nodes) is also 100%. For distant metastatic disease (Stage IVB), the five-year survival drops to about 40%.
These numbers reflect averages across large populations. Individual outcomes vary based on Grade Group, specific treatment, overall health, and how the cancer responds to therapy. Still, the data underscores why early detection matters so much: the vast majority of prostate cancers are caught while still localized, when the prognosis is excellent.
How Staging Is Determined
Several tests feed into the staging process. A digital rectal exam lets your doctor feel whether there’s a hard area on the prostate. A prostate biopsy, often guided by MRI or ultrasound, provides the tissue sample needed to assign a Grade Group. Your PSA blood level is measured as part of routine screening or follow-up.
MRI is particularly useful for seeing whether the cancer has pushed through the prostate wall or into the seminal vesicles, which is the dividing line between Stage II and Stage III. A bone scan checks for metastases in the skeleton. CT scans can reveal enlarged lymph nodes. For more ambiguous situations, such as a rising PSA after treatment with no obvious tumor on standard imaging, newer PET scans that target a protein on prostate cancer cells (called PSMA) can locate cancer that other scans miss. These PSMA-based scans have become increasingly important for detecting recurrence and guiding treatment decisions.